Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 2Completed 2Active not recruiting 2Terminated 1Suspended 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 5Specimen Handling 2Biopsy 2130-nm albumin-bound paclitaxel 2zimberelimab 1sotigalimab 1poly(I).poly(c12,U) 1palbociclib 1olaparib 1gedatolisib 1durvalumab 1Tomography, Optical Coherence 1Taxes 1Self Expandable Metallic Stents 1S 1 (combination) 1NUC-1031 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1IFL protocol 1Extracorporeal Shockwave Therapy 1Erlotinib Hydrochloride 1Disulfides 1Carnitine 1Calcitriol 1CA-4948 1Albumin-Bound Paclitaxel 1ABTL0812 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Pancreatic Neoplasms × palbociclib × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡